Active	Status	Sponsor type	Region	Phase	Filter
11 Active 3 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Phibbs, Fenna T
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
Antonini, Angelo
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	01/24	02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	522	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	06/24	06/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy	Active, not recruiting	2	159	Europe, Japan, US	TAK-341, MEDI1341, Placebo	Takeda, AstraZeneca	Multiple System Atrophy	07/25	07/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
Liang, Tsao-Wei
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
Safarpour
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26